Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369223 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 356
- Enrollment target
NCT03369223: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03369223 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 356 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (493% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03369223, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 356 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Primary Outcome
Adverse Events (AEs): Adverse events are any unwanted or harmful medical occurrences in a participant who receives a study drug or intervention. These events may or may not be related to the treatment. Serious Adverse Events (SAEs): Serious adverse events are adverse events that result in death, are life-threatening, require hospitalization or prolong existing hospitalization, cause significant disability or incapacity, or result in a birth defect.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL BMS-986249
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
What the finished NCT03369223 record still lists
NCT03369223 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (493% higher).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03369223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03369223 about?
NCT03369223 is a clinical study titled "A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors". The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
What is the current status of trial NCT03369223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 356 participants. The study started on 2017-12-06. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03369223?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986249 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03369223?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03369223's enrollment target sits among peer trials
356 95th of 2000 higher than 1,906 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI